Search

Your search keyword '"Drugs -- Marketing"' showing total 2,185 results
Start Over Descriptor "Drugs -- Marketing"
2,185 results on '"Drugs -- Marketing"'

1. OH, OH, OH, OZEMPIC: How benefits plan sponsors and insurers are managing newer - and effective -GLP-1 medications

Author

Smith, Brooke

Subjects
Novo Nordisk A/S -- Marketing -- Management, Advertising campaigns -- Marketing, Diabetes therapy -- Marketing, Drugs -- Marketing, Type 2 diabetes -- Drug therapy, Company marketing practices, Company business management, Banking, finance and accounting industries, Human resources and labor relations, Ozempic (Medication) -- Marketing, Wegovy (Medication) -- Marketing
Abstract

With lyrics adapted to the tunc of 'Magic' by Scottish pop group Pilot, the melody of'Oh, Oh. Oh, Ozempic' is splashed across U.S. televisions in a snappy advertising campaign. The [...]

Published
2024

2. McKesson price target lowered by $30 at Argus, here's why

Subjects
Drugs -- Marketing, Company marketing practices, Business, News, opinion and commentary
Abstract

Argus lowered the firm's price target on McKesson to $640 from $670 but keeps a Buy rating on the shares. The firm cites the recent market volatility driving its price [...]

Published
2024

3. Chugai to transfer future marketing of physiological intestinal function improving and hyperammonemia drug, Monilac in Japan to Maruishi Pharma

Subjects
Chugai Pharmaceutical Company Ltd. -- Marketing, Drugs -- Marketing, Marketing, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Chugai Pharmaceutical Co., Ltd., a research-based pharmaceutical company, and Maruishi Pharmaceutical Co., Ltd., a manufacturer of Japanese Pharmacopoeia medicines, announced that Chugai will transfer to Maruishi, the business in Japan [...]

Published
2024

4. 'Fatigue Recovery While You Sleep!' Eisai to Launch Designated Quasi-Drug Drink 'Chocola BB Nightwell'

Subjects
Eisai Company Ltd. -- Marketing, Fatigue, Dietary supplements -- Marketing, Drugs -- Marketing, Glycine -- Marketing, Sleep, Company marketing practices, Business, general
Abstract

- Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and Glycine - TOKYO, Mar 3, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today the launch of the new nutritional drink [...]

Published
2025

5. NEXT GENERATION TELEHEALTH PLATFORM LAUNCHES, COMBINING MEDICATIONS AND PERSONALIZED SUPPLEMENTS

Subjects
Marketing, Company marketing practices, Drugs -- Marketing, Combination drug therapy, Medical care quality, Semaglutide -- Marketing, Weight loss, Drug therapy, Combination, Medical care -- Quality management
Abstract

A New Era of Tailored Health: Personalized Health Rx Bridges Immediate Health Goals with Long-Term Wellness SNOQUALMIE, Wash., Jan. 14, 2025 /PRNewswire/ -- https://c212.net/c/link/?t=0&l=en&o=4339272-1&h=3192162199&u=https%3A%2F%2Fwww.personalizedhealthrx.com%2F&a=Personalized+Health+Rx%E2%84%A2(PHRx), a new direct-to-consumer telehealth platform under [...]

Published
2025

6. B&D Nutritional Ingredients Announces New Customer Product Launch--A Nutritional Supplement System Supporting GLP-1 Medication Users

Subjects
Dietary supplements industry -- Marketing, Dietary supplements -- Marketing, Drugs -- Marketing, Company marketing practices, General interest, News, opinion and commentary
Abstract

CARLSBAD, Calif: B&D Nutritional Ingredients has issued the following news release: B&D Nutritional Ingredients, Inc., a raw material distributor in the dietary supplement industry and exclusive U.S. distribution partner to [...]

Published
2024

9. EMA re-confirms non-renewal of authorisation of Duchenne muscular dystrophy medicine

Subjects
Dystrophin -- Genetic aspects, Duchenne muscular dystrophy -- Care and treatment -- Genetic aspects, Drugs -- Marketing, Utrophin -- Genetic aspects, Company marketing practices, Business, international
Abstract

London: European Medicines Agency has issued the following news release: Following a re-examination of available data, EMA's human medicines committee (CHMP) has confirmed its previous recommendation to not renew the [...]

Published
2024

10. My miracle weight-loss jab has changed my life and will change the world; A recent health scare was the final push I needed to banish shame and embrace a drug that might allow me to meet my grandchildren

Subjects
Drugs -- Marketing, Weight reducing preparations, Type 2 diabetes, Weight loss, Company marketing practices, General interest, News, opinion and commentary, Ozempic (Medication) -- Marketing, Mounjaro (Medication) -- Marketing
Abstract

Byline: Allison Pearson How many people do you know who are jabbing themselves with the new 'miracle' weight-loss drugs? Probably more than you realise. Put it this way, if you [...]

Published
2024

11. Semmelweis University Researchers Update Current Study Findings on Sustainability Research (A concept for multi-winner tenders for medicinal products with balancing between efficient prices, long-term competition and sustainability of supply)

Subjects
Management, Usage, Marketing, Company marketing practices, Company business management, Competitive bidding -- Usage, Drugs -- Marketing, Prescription pricing -- Management, Pharmaceutical industry -- Marketing -- Management, Letting of contracts -- Usage
Abstract

2023 NOV 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New study results on sustainability research have been published. According to news [...]

Published
2023

12. Gov't doctors may be part of drug firm marketing scam -- Ejercito

Author

Ager, Maila

Subjects
Drugs -- Marketing, Physicians, Marketing, Pharmaceutical industry -- Marketing, Company marketing practices, General interest, News, opinion and commentary
Abstract

Sen. Joseph Victor 'JV' Ejercito (File photo from the Senate Social Media Unit) MANILA, Philippines --- Even government doctors might have been involved in an alleged 'multi-level marketing networking' of [...]

Published
2024

13. HHS unveils first 10 drugs subject to Medicare price negotiation

Subjects
Bristol-Myers Squibb Co. -- Marketing, United States. Centers for Medicare and Medicaid Services, Marketing, Company marketing practices, Presidential elections, Medicare -- Marketing, Drugs -- Marketing, Political campaigns, Pharmaceutical industry -- Marketing, Prescriptions (Drugs) -- Marketing, Electioneering, Drugs -- Prescribing -- Marketing, Presidents -- Elections
Abstract

The Biden administration on Tuesday unveiled the 10 prescription drugs that will be eligible for price negotiation -- a major step forward in the implementation of legislation that passed last [...]

Published
2023

14. AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency

Subjects
Amyotrophic lateral sclerosis, Drugs -- Marketing, Marketing, Company marketing practices, Banking, finance and accounting industries, Business
Abstract

PRESS RELEASE AB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE EUROPEAN MEDICINES AGENCY A DECISION FROM THE EUROPEAN MEDICINES AGENCY [...]

Published
2024

15. Not All Greenness Is the Same: Associations with Health Are More Nuanced than We Thought

Author

Schmidt, Charles W.

Subjects
Influence, Care and treatment, Marketing, Environmental aspects, Health aspects, Company marketing practices, Public spaces -- Influence -- Environmental aspects -- Health aspects, Mood disorders -- Care and treatment, Drugs -- Marketing, Cardiovascular diseases -- Care and treatment, Affective disorders -- Care and treatment
Abstract

A growing body of evidence indicates that exposure to urban greenspaces, especially treed areas, benefits the health of city dwellers. (1-4) Now, new research in Environmental Health Perspectives finds that [...]

Published
2022
Full Text
View/download PDF

18. EMA's human medicines committee recommends marketing authorization for Novartis' Pluvicto to treat progressive PSMA-positive mCRPC

Subjects
Novartis AG -- Marketing, Pluvicto (Medication) -- Marketing, Marketing, Company marketing practices, Drugs -- Marketing, Chemotherapy, Prostate cancer, Cancer -- Chemotherapy
Abstract

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for [...]

Published
2022

19. Inside the gold rush to sell cheaper imitations of Ozempic

Subjects
United States. Food and Drug Administration, Novo Nordisk A/S -- Marketing, Drugs -- Marketing, Weight loss, Pharmaceutical industry -- Marketing, Company marketing practices, Business, Computers and office automation industries, Telecommunications industry, Ozempic (Medication) -- Marketing, Wegovy (Medication) -- Marketing
Abstract

Byline: Daniel Gilbert Ashley Dunham lost 100 pounds over the past year, but she didn't take Ozempic. Instead, she favors a cheaper, off-brand concoction made with Ozempic's active ingredient. 'This [...]

Published
2023

20. Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries

Subjects
Sanofi S.A. -- Marketing, Marketing, Company marketing practices, Drugs -- Marketing, Public health, Pharmaceutical industry -- Marketing
Abstract

Sanofi Global Health announces the launch of Impact, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the world's most [...]

Published
2022

21. Pharmacy Benefit Management Market Thrives on the Back of Growing Need to Raise Affordability of Specialty Drugs

Subjects
Drugstores -- Marketing, Drugs -- Marketing, Postal service -- Marketing, Company marketing practices, Company business management, General interest, News, opinion and commentary
Abstract

London: Fairfield Consultancy Services OPC Pvt Ltd has issued the following press release: The escalating demand for services with regards to pharmacy benefit management from drug manufacturing brands, retail pharmacy [...]

Published
2023

22. MHRA and Genomics England to launch pioneering resource to better understand how genetic makeup influences the safety of medicines

Subjects
Genetic research, Independent regulatory commissions, Drugs -- Marketing, Company marketing practices, Company joint venture, Business, international
Abstract

London: UK Government has issued the following news release: The Medicines and Healthcare products Regulatory Agency (MHRA) has today announced it will be the first drug safety regulator in the [...]

Published
2023

23. European Medicines Agency validates marketing authorization application for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer

Subjects
Diseases -- Relapse, Endometrial cancer, Drugs -- Marketing, Chemotherapy, Cancer -- Chemotherapy, Marketing, Company marketing practices, Business, Chemicals, plastics and rubber industries
Abstract

GSK plc announced on 25 Apr 2023 that the European Medicines Agency (EMA) validated the company's Type II Variation for a potential new indication for Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult patients with a type of gynaecological cancer known as mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. As a result, the EMA's Committee for Medicinal Products for Human Use will begin the formal review process to make a recommendation to the European Commission regarding marketing authorisation for the potential new indication. The regulatory submission is based on the interim results of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial. The trial met its primary endpoint of investigator-assessed progression-free survival (PFS), showing a statistically significant and clinically meaningful benefit versus placebo plus chemotherapy in patients treated with dostarlimab plus carboplatin-paclitaxel in the dMMR/MSI-H population. In addition, the safety and tolerability profile of dostarlimab in combination with carboplatin-paclitaxel was generally consistent with the known safety profiles of the individual agents. The results were presented on 27 Mar 2023 at a European Society for Medical Oncology Virtual Plenary and the Society of Gynecologic Oncology Annual Meeting and simultaneously published in The New England Journal of Medicine. GSK expects US regulatory filing review based on the RUBY phase III trial results in occur in the 1H 2023. Original source: GlaxoSmithKline, website: http://www.gsk.com/, Copyright GlaxoSmithKline plc 2023., regulations and rulings; research and development; anticancer drugs; dostarlimab; Jemperli; monoclonal antibodies; therapeutic antibodies; [...]

Published
2023

24. Submission Considerations for Orphan Product Programs: Examining the unique aspects involved in preparing and submitting marketing applications for proposed treatments for rare disease

Author

Woolson, Rob and Barber, Kevin

Subjects
Prevention, Marketing, Company marketing practices, Drugs -- Marketing, Medical research, Biological markers, Diseases
Abstract

In developing drugs to treat or prevent rare diseases, the overall challenge is designing and executing an efficient, effective development program while educating stakeholders, including FDA, about the disease or [...]

Published
2019

29. Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement

Subjects
Drugs -- Marketing, Proteins, Venture capital companies -- Marketing, Company marketing practices, General interest, News, opinion and commentary
Abstract

WATERTOWN: ENTACT BIO has issued the following news release: Entact Bio, the company pioneering the development of precision medicines that enhance the function of key proteins, today announced it has [...]

Published
2022

30. Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement

Subjects
Drugs -- Marketing, Proteins, Venture capital companies -- Marketing, Company marketing practices, Business, Business, international
Abstract

Launch fueled by syndicate of blue-chip investors co-led by Qiming Venture Partners USA and venBio Partners Company's proprietary end-to-end Encompass[TM] platform designs enhancement-targeting chimeric (ENTAC[TM]) molecules Founding team comprised of [...]

Published
2022

31. European Medicines Agency accepts marketing authorization application for momelotinib for the treatment of myelofibrosis

Subjects
Drugs -- Marketing, Drug approval, Marketing, Company marketing practices, Business, Chemicals, plastics and rubber industries
Abstract

GSK plc announced on 2 Dec 2022 that the European Medicines Agency (EMA) validated the marketing authorization application (MAA) for momelotinib, a potential new oral treatment for myelofibrosis. Momelotinib has a differentiated mechanism of action, with inhibitory ability along three key signalling pathways: Janus kinase (JAK) 1, and JAK2 and activin A receptor type I (ACVR1), which could address the significant medical needs of myelofibrosis patients with anaemia. The MAA is based on results from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary endpoints, including Total Symptom Score (TSS), Transfusion Independence (TI) rate and Splenic Response Rate (SRR). The primary analysis data from the MOMENTUM phase III trial were presented at the 2022 American Society of Clinical Oncology Annual Meeting and the European Hematology Association 2022 Hybrid Congress. Updated 48-week data will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition on 10-13 Dec 2022. A Committee for Medicinal Products for Human Use (CHMP) regulatory action is anticipated by year-end 2023, and a New Drug Application for momelotinib is currently under regulatory review with the US Food and Drug Administration (FDA) with a Prescription Drug User Fee Act action date of 16 Jun 2023. Momelotinib is not currently approved in any market, but if approved by regulators, momelotinib would be the only medicine that addresses key manifestations of myelofibrosis, including anaemia, symptoms, and splenomegaly. Original source: GlaxoSmithKline, website: http://www.gsk.com/, Copyright GlaxoSmithKline plc 2022., regulations and rulings; research and development; anticancer drugs; enzyme inhibitors; momelotinib; [...]

Published
2022

35. Sanofi Global Health launches nonprofit Impact brand for 30 medicines in low-income countries

Subjects
Sanofi S.A. -- Marketing, Drugs -- Marketing, Company marketing practices, Business, Chemicals, plastics and rubber industries
Abstract

Sanofi Global Health announces the launch of Impact, a new brand of standard of care medicines produced by Sanofi dedicated for nonprofit distribution to at-risk populations in the world's most impoverished countries. The Impact brand, which includes insulin, glibenclamide and oxaliplatin amongst others, will enable the secure distribution of 30 Sanofi medicines in 40 lower-income countries. Considered essential by the World Health Organization, the medicines cover a wide range of therapeutic areas, including diabetes, cardiovascular disease, tuberculosis, malaria and cancer. The launch of the Impact brand is among the steps taken since the formation in 2021 of Sanofi Global Health, a nonprofit unit within the company aiming to increase access to healthcare through the distribution of medicines, and the building and bolstering of local healthcare systems in countries with among the lowest per capita GDP. Sanofi Global Health is the first and only global initiative to provide access to such a broad portfolio of medicines in so many countries and across multiple therapeutic areas while funding local support programs and strengthening local inclusive businesses. The company also announces the establishment of an Impact fund that will support startup companies and other innovators that can deliver scalable solutions for sustainable healthcare in underserved regions. By providing inclusive businesses financing and technical assistance, the fund will complement the GHU mission of leveraging global, regional and local investment to support the training of healthcare professionals and aiding communities in running sustainable care systems. The announcements come as Sanofi gathers key global health stakeholders to discuss how to build effective end-to-end health programs that are embedded in the communities in which they serve, to best reach, treat and manage patients' health effectively and sustainably. Original source: Sanofi, website: http://en.sanofi.com/, Copyright Sanofi 2022., new material; flutriafol; glibenclamide; insulin; oxaliplatin; [...]

Published
2022

36. Sanofi Global Health launches nonprofit ImpactA[R] brand for 30 medicines in low-income countries

Subjects
Sanofi S.A. -- Marketing, World health, Drugs -- Marketing, Pharmaceutical industry -- Marketing, Company marketing practices, Business, Business, international
Abstract

M2 PRESSWIRE-July 4, 2022-: Sanofi Global Health launches nonprofit ImpactÂ[R] brand for 30 medicines in low-income countries (C)1994-2022 M2 COMMUNICATIONS RDATE:04072022 - Medicines, including insulin, to be available in 40 [...]

Published
2022

37. Sanofi Global Health launches nonprofit Impact(R) brand for 30 medicines in low-income countries

Subjects
Sanofi S.A. -- Marketing, World health, Drugs -- Marketing, Pharmaceutical industry -- Marketing, Company marketing practices, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Sanofi Global Health launches nonprofit Impact(R) brand for 30 medicines in low-income countries - Medicines, including insulin, to be available in 40 lower-income countries - [...]

Published
2022

38. Anne Marie Morris ask the Secretary of State for Health and Social Care, what the five highest health gain categories are in respect of the Voluntary scheme for branded medicines pricing and access, published in December 2018

Subjects
Pricing, Drugs -- Marketing, Ivacaftor, Company marketing practices, Product price, Business, international
Abstract

London: UK Parliament has issued the following written answer: Answer Edward Argar Answered on 27 June 2022 The Voluntary Scheme for Branded Medicines Pricing and Access is an agreement between [...]

Published
2022

39. Bempedoic acid market in India will become crowded soon with more generic launches, says GlobalData

Subjects
Statins, Drugs -- Marketing, Drug approval, Cardiovascular diseases, Company marketing practices, Business, Chemicals, plastics and rubber industries
Abstract

Zydus Lifesciences launched a first-in-class oral, non-statin lipid-lowering drug, bempedoic acid, under the brand name Bemdac, for the first time in India in May 2022. Considering bempedoic acid is a novel drug, multiple Indian pharma companies are expected to launch bempedoic acid under their brand names in the country. Against this backdrop, the bempedoic acid market in India will become crowded soon, says GlobalData, a leading data and analytics company. Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe. Moreover, it has shown promising results in patients intolerant to statins and patients not responding to statins. The focus on bempedoic acid by Indian pharma companies has increased drastically. Within eight days of the launch by Zydus Lifesciences, three companies Sun Pharma, Akum Drugs & Pharmaceuticals Ltd and Cadila Pharma have already announced plans to launch bempedoic acid in India. In Feb 2020, the FDA approved Esperion's bempedoic acid under the brand name Nexletol and EMA approved it in Apr 2020 under the brand name Nilemdo. Notably, there are no generics available for bempedoic acid in the US or Europe. Furthermore, none of the Indian players have any partnership with Esperion for bempedoic acid. Original source: Global Data, website: http://www.energy.globaldata.com, Copyright Global Data 2022., joint venture; market; new material; Bemdac; bempedoic acid; cardiovascular drugs; ezetimibe; generic pharmaceuticals; Nexletol; Nilemdo; statins; Akum Drugs & Pharmaceuticals; Cadila Pharma; Esperion; Sun Pharma; Zydus [...]

Published
2022

40. Misusing FSSAI licences, several Siddha drugs are marketed as herbal products by marketing cos in Chennai

Subjects
Drugs -- Marketing, Food safety, Herbal medicine, Marketing, Safety regulations, Company marketing practices, Pharmaceuticals and cosmetics industries
Abstract

Byline: Peethaambaran Kunnathoor Although the Food Safety and Standards Act (FSSA) was drafted carefully and it seems largely foolproof, certain provisions in the Act are alleged to be creating regulatory [...]

Published
2020

43. Lay theories of medicine and a healthy lifestyle

Author

Wang, Wenbo, Keh, Hean Tat, and Bolton, Lisa E.

Subjects
Consumer behavior -- Research, Health products -- Marketing, Health products -- Public opinion, Drugs -- Marketing, Drugs -- Public opinion, Company marketing practices, Advertising, marketing and public relations, Social sciences
Abstract

A study was conducted to show that consumers hold 'lay theories of medicine' that guide their preferences and behaviors in the health domain. These theories include lay beliefs about illnesses and symptoms and lay beliefs about health remedies. Western medicine and its Eastern counterparts are also examined.

Published
2010

44. Hidden in plain sight: marketing prescription drugs to consumers in the twentieth century

Author

Greene, Jeremy A. and Herzberg, David

Subjects
Drugs -- Marketing, Pharmaceutical industry -- Marketing, Public health -- Research, Company marketing practices, Government, Health care industry
Abstract

Although the public health impact of direct to consumer (DTC) pharmaceutical advertising remains a subject of great controversy. such promotion is typically understood as a recent phenomenon permitted only by changes in federal regulation of print and broadcast advertising over the past two decades. But today's omnipresent ads are only the most recent chapter in a longer history of DTC pharmaceutical promotion (including time ghostwriting of popular articles, organization of public-relations events, and implicit advertising of products to consumers) stretching back over the twentieth century. We use trade literature and archival materials to examine the continuity of efforts to promote prescription drugs to consumers and to better grapple with the public health significance of contemporary pharmaceutical marketing practices. (Am J Public Health. 2010;100:793-803. doi: 10.2105/AJPH.2009.181255)

Published
2010

45. The Accelerating Access Initiative: experience with a multinational workplace programme in Africa/Initiative Accelerer l'Acces: experience acquise avec un programme de delivrance des ARV au poste de travail, mene par une multinationale en Afrique/Iniciativa para Acelerar el Acceso: experiencia de un programa en los centros de trabajo de una multinacional en Africa

Author

Van der Borght, S., Janssens, V., van der Loeff, M.F. Schim, Kajemba, A., Rijckborst, H., Lange, J.M.A., and de Wit, T.F. Rinke

Subjects
United Nations. Population Fund, Domestic policy, Care and treatment, Marketing, Company marketing practices, Insurance industry, Insurance industry -- Marketing, AIDS (Disease) -- Care and treatment, Drugs -- Marketing, Employers, HIV -- Care and treatment, Antiretroviral agents, Multinational corporations, HIV (Viruses) -- Care and treatment, Antiviral agents, International business enterprises
Abstract

Problem HIV is the largest threat to adult survival in sub-Saharan Africa. According to UNAIDS, 33 million people were living with HIV by December 2007, of whom 22 million were [...], Problem A multinational company with operations in several African countries was committed to offer antiretroviral treatment to its employees and their dependants. Approach The Accelerating Access Initiative (MI), an initiative of six pharmaceutical companies and five United Nations' agencies, offered the possibility of obtaining brand antiretroviral drugs (ARVs) at 10% of the commercial price. PharmAccess, a foundation aimed at removing barriers to AIDS treatment in Africa, helped to establish an HIV policy and treatment guidelines, and a workplace programme was rolled out from September 2001. Local setting Private sector employers in Africa are keen to take more responsibility in HIV prevention and AIDS care. An important hurdle for African employers remains the price and availability of ARVs. Relevant changes The programme encountered various hurdles, among them the need for multiple contracts with multiple companies, complex importation procedures, taxes levied on ARVs, lack of support from pharmaceutical companies in importation and transportation, slow delivery of the drugs, lack of institutional memory in pharmaceutical companies and government policies excluding the company from access to ARVs under the AAI. Lessons learned The launch of the AAI enabled this multinational company to offer access to ARVs to its employees and dependants. The private sector should have access to these discounted drugs under the AAI. A network of Local AAI offices should be created to assist in logistics of drugs ordering, purchase and clearance. No taxes should be levied on ARVs. Problematique Une entreprise multinationale operant dans plusieurs pays africains s'est engagee a proposer un traitement antiretroviral a ses employes et a leurs dependants. Demarche L'lnitiative Accelerer l'Acces (IAA), impliquant six entreprises pharmaceutiques et cinq agences des Nations Unies, offre la possibilite d'acquerir des antiretroviraux (ARV) de marque a un dixieme de leur prix dans le commerce. PharmAcces, une fondation visant a eliminer les obstacles au traitement du sida en Afrique, a aide a mettre en place une politique contre le VlH, ainsi que des recommandations therapeutiques, et un programme de lutte contre cette maladie au poste de travail a ete mis en route en septembre 2001. Contexte local En Afrique, les employeurs du secteur prive souhaiteraient prendre plus de responsabilites dans la prevention du VlH et la prestation de soins concernant le sida. Le prix et le manque de disponibilite des ARV restent un obstacle important dans cette voie. Modifications pertinentes Le programme s'est heurte a diverses difficultes, dont la necessite de passer de multiples contrats avec un grand nombre d'entreprises, la complexite des procedures d'importation, les taxes prelevees sur les ARV, le manque de soutien des entreprises pharmaceutiques pour l'importation et le transport de ces medicaments, la lenteur de leur livraison, le manque de memoire institutionnelle de l'industrie pharmaceutique et les politiques gouvernementales interdisant aux entreprises d'acceder aux ARV par le biais de l'IAA. Enseignements tires Le lancement de l'IAA a permis a cette entreprise multinationale de proposer un acces aux ARV a ses employes et a leurs dependants. Le secteur prive devrait avoir acces a des ARV a prix reduit dans le cadre de l'IAA. II faudrait aussi creer un reseau de bureaux Iocaux de l'IAA pour apporter une assistance Iogistique dans la commande, l'acquisition et l'autorisation de ces medicaments. Aucune taxe ne devrait etre prelevee sur les ARV. Problema Una multinacional que operaba en varies paises africanos se comprometio a ofrecer tratamiento antirretroviral a sus empleados y a sus familiares a cargo. Enfoque La Iniciativa para Acelerar el Acceso (IAA), en la que participan seis empresas farmaceuticas y cinco organismos de las Naciones Unidas, ofrecio la posibilidad de obtener antirretrovirales (ARV) comerciales a un 10% dei precio habitual. PharmAccess, una fundacion cuyo objetivo es eliminar las barreras al tratamiento del sida en Africa, ayudo a establecer una politica y directrices terapeuticas para la infeccion por VIH, y a partir de septiembre de 2001 se puso en marcha un programa para los centros de trabajo. Contexto local Los empleadores del sector privado de Africa tienen gran interes en asumir mas responsabilidad en la prevencion de la infeccion por VIH y la atencion a los enfermos de sida, pero el piecio y la disponibilidad de ARV siguen siendo obstaculos importantes para ellos. Cambios destacables EI programa tropezo con diversos obstaculos, entre ellos la necesidad de multiples contratos con diversas empresas, unos procedimientos de importacion complejos, los impuestos que gravaban los antirretrovirales, la falta de apoyo de las empresas farmaceuticas para la importacion y el transporte, la lentitud del suministro de los medicamentos, la falta de memoria institucional en las companias farmaceuticas, y las politicas gubernamentales que impedian a la empresa acceder a los antirretrovirales en el marco de la IAA. Ensenanzas extraidas El lanzamiento de la IAA permitio a esta multinacional ofrecer acceso a los ARV a sus empleados y sus familiares a cargo. El sector privado deberia tener acceso a esos medicamentos con descuento en el marco de la IAA. Se deberia crear una red de oficinas Iocales de IAA que facilitaran la logistica de los pedidos, la autorizacion y la compra de los medicamentos. Por ultimo, los ARV no deberian estar sujetos a impuestos.

Published
2009

46. How does drug and supplement marketing affect a healthy lifestyle?

Author

Bolton, Lisa E., Reed, Americus II, Volpp, Kevin G., and Armstrong, Katrina

Subjects
Drugs -- Marketing, Drugs -- Psychological aspects, Health behavior -- Psychological aspects, Company marketing practices, Advertising, marketing and public relations, Social sciences
Abstract

Drug marketing undermines consumer intentions to engage in health-protective behaviors through the boomerang effect. Psychological mechanisms involving drugs contribute to the boomerang effect.

Published
2008

48. Drug target identified for chemotherapy-resistant ovarian, breast cancer

Subjects
Breast cancer, Drugs -- Marketing, Ovarian cancer, Chemotherapy, Women's health, Cancer genetics, Tumors, Genes, Anopheles, Editors, Company marketing practices, Health, Women's issues/gender studies
Abstract

2019 FEB 21 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- People who inherit a faulty copy of the so-called 'breast cancer genes' BRCA1 and [...]

Published
2019

49. The debate on influencing doctors' decisions: are drug characteristics the missing link?

Author

Venkataraman, Sriram and Stremersch, Stefan

Subjects
Drugs -- Marketing, Pharmaceutical industry -- Marketing, Decision-making, Company marketing practices, Business, Business, general
Abstract

Decision making by physicians on patients' treatment has come under increased public scrutiny. In fact, there is a fair amount of debate on the effects of marketing actions of pharmaceutical firms toward physicians and their impact on physician prescription behavior. While some scholars find a strong and positive influence of marketing actions, some find only moderate effects, and others even find negative effects. Debate is also mounting on the role of other influencers (such as patient requests) in physician decision making, both on prescriptions and sample dispensing. The authors argue that one factor that may tip the balance in this debate is the role of drug characteristics, such as a drug's effectiveness and a drug's side effects. Using a unique data set, they show that marketing efforts--operationalized as detailing and symposium meetings of firms to physicians--and patient requests do affect physician decision making differentially across brands. Moreover, they find that the responsiveness of physicians' decision making to marketing efforts and patient requests depends upon the drug's effectiveness and side effects. This paper presents clear guidelines for public policy and managerial practice and envisions that the study of the role of drug characteristics, such as effectiveness and side effects, may lead to valuable insights in this surging public debate. Key words: physician decision making; marketing effort; patient request; drug effectiveness; side effect; drug prescription; sampling; sample dispensing; detailing; pharmaceuticals; public policy, 1. Introduction Decision making by physicians regarding the drugs they treat patients with has come under increased scrutiny. As pharmaceutical expenses in the United States and other developed countries rise [...]

Published
2007

50. Time to ban direct-to-consumer prescription drug marketing

Author

Stange, Kurt C.

Subjects
Pharmaceutical industry -- Laws, regulations and rules, Pharmaceutical industry -- Marketing, Drugs -- Marketing, Marketing -- Laws, regulations and rules, Direct marketing -- Laws, regulations and rules, Government regulation, Company marketing practices, Health, Science and technology
Published
2007

Catalog

Books, media, physical & digital resources
See catalog results